Literature DB >> 26782938

The Contemporary Use of Angiography and Revascularization Among Patients With Non-ST-Segment Elevation Myocardial Infarction in the United States Compared With South Korea.

Hyun-Jae Kang1,2, Dajuanicia Simon3, Tracy Y Wang1, Karen P Alexander1, Myung Ho Jeong4, Hyo-Soo Kim5, Eric R Bates6, Timothy D Henry7, Eric D Peterson1, Matthew T Roe1.   

Abstract

BACKGROUND: Practice guidelines recommend an early invasive strategy for high-risk non-ST-segment elevation myocardial infarction (NSTEMI) patients, but international differences in the use of invasive strategies are unknown. HYPOTHESIS: Profiling NSTEMI patient management in the United States (U.S.) and South Korea could provide insight into how patients are triaged for an early invasive strategy in different health care environments and geographical regions.
METHODS: We evaluated the use of angiography and revascularization for NSTEMI patients treated at revascularization-capable hospitals (2007-2010) in both the ACTION Registry-GWTG (U.S.: n = 133,835; 433 hospitals) and KAMIR/KorMI Registry (South Korea: n = 7,901; 72 hospitals).
RESULTS: Compared with South Korean patients, U.S. NSTEMI patients more commonly had established cardiovascular risk factors, disease, and prior cardiovascular events and procedures. From 2007-2010, the use of angiography for NSTEMI patients rose steadily in both countries, but the use of revascularization only rose in South Korea. Patients from South Korea more commonly underwent angiography and revascularization. Percutaneous coronary intervention was the most common type of revascularization in both countries, but coronary artery bypass grafting was less common in South Korea. The use of both angiography and revascularization was incrementally lower with a higher predicted mortality risk for patients from both countries, but greater differences between low- and high-risk patients occurred in the U.S.
CONCLUSIONS: The profile, characteristics, and use of angiography and revascularization for NSTEMI patients in the U.S. vs South Korea differed substantially from 2007-2010, underscoring the heterogeneity of NSTEMI patients and treatment selection among different countries.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26782938      PMCID: PMC6490800          DOI: 10.1002/clc.22475

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  4 in total

1.  Invasive treatment strategy in patients aged 80 years or older with non-ST-elevation acute coronary syndromes: a retrospective cohort study.

Authors:  Dai Zhang; Yun-Li Xing; Huan Wang; Shan Wang; Ye Miao; Wei Huang; Kan Zhang; Hong-Wei Li; Ying Sun; Hui Chen
Journal:  Cardiovasc Diagn Ther       Date:  2022-04

2.  Temporal trends and inequalities in coronary angiography utilization in the management of non-ST-Elevation acute coronary syndromes in the U.S.

Authors:  Muhammad Rashid; David L Fischman; Martha Gulati; Khalid Tamman; Jessica Potts; Chun Shing Kwok; Joie Ensor; Ahmad Shoaib; Hossam Mansour; Azfar Zaman; Michael P Savage; Mamas A Mamas
Journal:  Sci Rep       Date:  2019-01-18       Impact factor: 4.379

Review 3.  Invasive and antiplatelet treatment of patients with non-ST-segment elevation myocardial infarction: Understanding and addressing the global risk-treatment paradox.

Authors:  Ingo Ahrens; Oleg Averkov; Eduardo C Zúñiga; Alan Y Y Fong; Khalid F Alhabib; Sigrun Halvorsen; Muhamad A B S K Abdul Kader; Ricardo Sanz-Ruiz; Robert Welsh; Hongbin Yan; Philip Aylward
Journal:  Clin Cardiol       Date:  2019-07-17       Impact factor: 2.882

4.  Current Status and Hospital-Level Differences in Care and Outcomes of Patients With Acute Non-ST-Segment Elevation Myocardial Infarction in China: Insights From China Acute Myocardial Infarction Registry.

Authors:  Qinghao Zhao; Haiyan Xu; Xuan Zhang; Yunqing Ye; Qiuting Dong; Rui Fu; Hui Sun; Xinxin Yan; Xiaojin Gao; Jingang Yang; Yang Wang; Yuejin Yang
Journal:  Front Cardiovasc Med       Date:  2022-01-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.